[go: up one dir, main page]

MX2018009804A - Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer. - Google Patents

Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.

Info

Publication number
MX2018009804A
MX2018009804A MX2018009804A MX2018009804A MX2018009804A MX 2018009804 A MX2018009804 A MX 2018009804A MX 2018009804 A MX2018009804 A MX 2018009804A MX 2018009804 A MX2018009804 A MX 2018009804A MX 2018009804 A MX2018009804 A MX 2018009804A
Authority
MX
Mexico
Prior art keywords
patient
therapeutic targets
cancer immunotherapies
throughput identification
specific neoepitopes
Prior art date
Application number
MX2018009804A
Other languages
English (en)
Inventor
Soon-Shiong Patrick
Nguyen Andrew
Niazi Kayvan
Rabizadeh Shahrooz
Charles Benz Stephen
Zachary Sanborn John
Joseph Vaske Charles
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of MX2018009804A publication Critical patent/MX2018009804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Se presentan sistemas y métodos que permiten la selección de neoepítopos tumorales que se filtran según diversos criterios. En aspectos particularmente contemplados, la filtración incluye un paso en el que se determina que la mutación que conduce al neoepítopo está localizada en un gen controlador de cáncer.
MX2018009804A 2016-02-12 2017-02-10 Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer. MX2018009804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294665P 2016-02-12 2016-02-12
PCT/US2017/017549 WO2017139694A1 (en) 2016-02-12 2017-02-10 High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies

Publications (1)

Publication Number Publication Date
MX2018009804A true MX2018009804A (es) 2018-11-09

Family

ID=59564011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009804A MX2018009804A (es) 2016-02-12 2017-02-10 Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.

Country Status (12)

Country Link
US (2) US11361841B2 (es)
EP (1) EP3414692A4 (es)
JP (1) JP2019511907A (es)
KR (1) KR20180091119A (es)
CN (1) CN108701172A (es)
AU (1) AU2017217877A1 (es)
CA (1) CA3014252A1 (es)
IL (1) IL261090A (es)
MX (1) MX2018009804A (es)
SG (1) SG11201806282XA (es)
TW (1) TW201739919A (es)
WO (1) WO2017139694A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11361841B2 (en) 2016-02-12 2022-06-14 Nantomics Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109979526B (zh) * 2014-03-25 2023-11-24 凡弗3基因组有限公司 用于功能证实癌症突变的rna分析的系统和方法
HUE064978T2 (hu) 2016-06-29 2024-04-28 Tesaro Inc A petefészekrák kezelésének módszerei
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
EP3679577A4 (en) * 2017-09-06 2021-06-02 Nant Holdings IP, LLC HLA TISSUE CALIBRATION AND PROCEDURE FOR IT
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
BR112020013214A2 (pt) * 2017-12-27 2020-12-01 Tesaro, Inc. métodos para tratar um câncer
KR20200136977A (ko) 2018-03-28 2020-12-08 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀으로부터 단리된 dna에서의 후성유전학적 변화의 식별
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020022898A2 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
US20220144926A1 (en) * 2018-10-16 2022-05-12 Board Of Regents, The University Of Texas System Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
GB201817651D0 (en) * 2018-10-29 2018-12-12 Univ College Dublin Nat Univ Ireland Dublin Method for predicting effectiveness of treatments for cancer patients
WO2020092038A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Cdkn2a screening germline expression
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
WO2020117853A1 (en) * 2018-12-04 2020-06-11 Nantomics, Llc Methods of making therapeutic t lymphocytes
WO2020176726A1 (en) * 2019-02-27 2020-09-03 Epivax Oncology, Inc. Improved compositions and methods for personalized neoplasia vaccines
CN110286235B (zh) * 2019-07-10 2022-07-15 郑州大学 一种用于肝癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法
EP4116436A4 (en) * 2020-01-07 2024-01-31 Korea Advanced Institute of Science and Technology METHOD AND SYSTEM FOR SCREENING NEOANTIGENS AND USES THEREOF
CN112980948B (zh) * 2020-08-28 2023-03-21 中山大学附属口腔医院 Nfat3作为治疗靶点在筛选或制备头颈部鳞状细胞癌药物中的应用
CN112725454B (zh) * 2021-02-03 2021-08-03 山东第一医科大学附属省立医院(山东省立医院) 膀胱癌患者总体生存率预后模型
CN113755594B (zh) * 2021-09-26 2024-05-14 中国医学科学院肿瘤医院 一种预测小细胞肺癌辅助化疗获益和识别化疗耐药治疗靶点的系统和应用
CN118561958B (zh) * 2024-05-20 2025-07-22 江苏海洋大学 肺癌新抗原多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575070B2 (en) 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
US7664689B1 (en) 2003-06-24 2010-02-16 Evercom Systems, Inc. Systems and methods for transaction and information management
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
AU2003295502A1 (en) * 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
CA2518569C (en) 2003-03-10 2011-11-15 Expression Pathology, Inc. Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
CN104774931B (zh) * 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CN101039953B (zh) * 2004-07-23 2012-08-15 沃尔特及伊莱萨霍尔医学研究院 治疗和诊断剂
JP2008535868A (ja) * 2005-04-14 2008-09-04 ザ ユニバーシティー オブ クイーンズランド 免疫調節組成物およびそのための使用
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CA2797645C (en) 2010-05-25 2020-09-22 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
BR112013004288A2 (pt) * 2010-08-23 2016-05-31 Selecta Biosciences Inc formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
JP2015533473A (ja) * 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
AU2013289883B2 (en) * 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
CA3137846A1 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CN108513593A (zh) * 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
US20170017749A1 (en) 2015-07-15 2017-01-19 International Business Machines Corporation System and method for identifying cancer driver genes
KR102211461B1 (ko) 2015-08-25 2021-02-03 난토믹스, 엘엘씨 고-정확도 변이 판정을 위한 시스템들 및 방법들
EP3362797B1 (en) * 2015-10-12 2025-04-23 Nantomics, LLC Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
HK1258091A1 (zh) 2015-10-12 2019-11-01 Nantomics, Llc 用於发现预测对检查点抑制剂敏感的 msi 和新表位的系统、组合物和方法
MX2018009804A (es) 2016-02-12 2018-11-09 Nantomics Llc Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11361841B2 (en) 2016-02-12 2022-06-14 Nantomics Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies

Also Published As

Publication number Publication date
US20220270709A1 (en) 2022-08-25
EP3414692A4 (en) 2020-07-29
CN108701172A (zh) 2018-10-23
AU2017217877A1 (en) 2018-08-16
JP2019511907A (ja) 2019-05-09
US11361841B2 (en) 2022-06-14
TW201739919A (zh) 2017-11-16
KR20180091119A (ko) 2018-08-14
IL261090A (en) 2018-10-31
CA3014252A1 (en) 2017-08-17
SG11201806282XA (en) 2018-08-30
US20190034582A1 (en) 2019-01-31
EP3414692A1 (en) 2018-12-19
WO2017139694A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
MX2018009804A (es) Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
MX2022005473A (es) Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de se?al regulada (erk).
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
EP4553840A3 (en) Systems and methods for analyzing nucleic acid
MX2023006229A (es) Sistemas y metodos para identificar y expresar agrupaciones de genes.
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
ECSP17084270A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
WO2016040524A8 (en) Methods and compositions for rapid nucleic acid library preparation
UY37143A (es) Compuestos macrocíclicos útiles como inmunomoduladores de las interacciones proteína/proteína pd-1/pd-l1 y cd80/pd-l1
WO2015132670A3 (en) Methods and compositions for detection of targets for autoimmune disease
MX2019011017A (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.
CA2973769C (en) Systems and methods for meso-dissection
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
EA202091497A3 (ru) Генетические локусы, связанные с повышенной фертильностью у маиса
MX2023002591A (es) Interfaces de proteina.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
BR112018016240A2 (pt) método de sequência alvo direta que utiliza proteção da nuclease
BR112016015595A2 (pt) métodos de determinação de câncer de pulmão